secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001104659-24-029097
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE reports Q4/FY 2023 loss; cash $93.3M; VYN201 Phase 2b starts Q2 2024; VYN202 Phase 1a expected Q2 2024
--------------------------------------------------------------------------------

- Cash, cash equivalents, restricted cash and marketable securities $93.3M at Dec 31, 2023, providing runway through end of 2025.
- GAAP loss from continuing ops Q4 2023 $6.15M vs $7.76M in Q4 2022; full year $27.87M vs $33.95M (improved YoY).
- Adjusted net loss Q4 2023 $5.48M vs $8.88M; full year $25.15M vs $18.91M (wider YoY for FY).
- VYN201 Phase 2b trial in nonsegmental vitiligo to begin Q2 2024; top-line results mid-2025; gel formulation selected.
- VYN202 IND submitted Dec 2023; FDA requested additional nonclinical study; completed consistent with expectations; Phase 1a expected Q2 2024 if FDA clears.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/0001104659-24-029097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465924029097/tm247462d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer